Covalon Technologies Ltd Stock Price, News & Analysis

Covalon Technologies Ltd. (CVALF) is hosting a webinar titled "Protecting CVADs from Gross Contamination" on March 29, 2023, to combat the rising incidents of central line-associated bloodstream infections (CLABSIs), which have surged by 47% since the COVID-19 pandemic according to the CDC. The session, led by expert Matthew Ostroff, will discuss innovative solutions to prevent CLABSIs, particularly in pediatric healthcare settings. This webinar is part of Covalon's CLABSI Conscious campaign aimed at improving patient safety and reducing infection rates through advanced medical technology and expert guidance.

Covalon Technologies Ltd., trading under the symbol CVALF, recently announced its participation in the Synova NICU Leadership Forum from March 19 to March 23, 2023, in Tucson, Arizona. The company will showcase its innovative infection prevention solutions at booth 106, emphasizing compassion in patient care, particularly for NICU and pediatric patients. Covalon's products, like the CovaClear IV and VALGuard, aim to improve patient outcomes while reducing stress for healthcare providers. Six of the top ten children's hospitals have adopted these solutions.

Covalon Technologies Ltd. announced the results of its Fiscal 2022 Annual and Special Meeting of Shareholders held on March 8, 2023. Shareholders approved all matters including the election of the Board of Directors, the appointment of auditors, and the Omnibus Long-Term Incentive Plan. A total of 12,803,487 shares, or 51.076%, were represented at the meeting. Notable voting results included Amir Boloor receiving 92.275% support and PricewaterhouseCoopers receiving 99.996% approval as auditors. The detailed voting results will be filed on SEDAR with further information available in the management information circular dated February 1, 2023.

Covalon Technologies Ltd. announced on March 9, 2023, the appointment of Martin Goldfarb to its Board of Directors. Goldfarb, a long-standing shareholder, has over a decade of involvement with Covalon and brings substantial experience in brand and strategic development. CEO Brian Pedlar expressed enthusiasm for Goldfarb's insights, highlighting his extensive entrepreneurial background. Goldfarb's previous roles include Chairman of Almada Inc. and President of Goldfarb Ventures. His appointment is subject to TSX approval. Covalon is focused on innovating healthcare by developing advanced medical technologies aimed at improving patient outcomes.

Covalon Technologies Ltd. (CVALF) announced its annual and special shareholder meeting scheduled for March 8, 2023, at 3:30 PM EST, to be held virtually. Registered shareholders and proxyholders can attend through a live webcast. Non-registered shareholders must appoint themselves as proxyholders to vote online. The meeting will cover important company matters and allow shareholder participation.

Details for accessing the meeting can be found on the company’s official website. Additional resources like the Management Information Circular and financial statements are available on SEDAR.

Covalon Technologies reported a strong fiscal Q1 2023 with a 25% revenue growth, totaling $6.2 million, compared to $4.9 million in Q1 2022. The company achieved a 60% gross margin, significantly up from 46% year-over-year, attributed to improved supply chain and operational efficiencies. Net loss narrowed to $0.4 million or $0.02 per share, compared to $1.5 million or $0.06 per share last year. Covalon continues to strengthen its market presence, particularly in the U.S., and has a solid cash position of $14.1 million with no debt, fueling future growth initiatives.

Covalon Technologies Ltd. (OTCQX: CVALF) will participate in the NEO Conference for Neonatology in Las Vegas from February 22 to 24, 2023. This marks the company's first appearance at the event, aimed at enhancing neonatal care through innovative solutions. Covalon's products focus on preventing infections in infants, significantly aiding top pediatric hospitals in the U.S. The company offers solutions such as VALGuard and IV Clear. With a commitment to improving patient outcomes, Covalon emphasizes compassionate care, which is vital for vulnerable neonates.

Covalon Technologies Ltd. (TSXV: COV, OTCQX: CVALF) will release its Q1 Fiscal 2023 financial results on February 23, 2023, before markets open. A conference call and webcast are scheduled for the same day at 9:00 am EST. Participants can join the call by dialing North American Toll-Free: 1-888-664-6392 or through a provided link for a callback option. The call will allow participants to engage in a Q&A session with management. Financial statements will be available on SEDAR and Covalon's website. The company focuses on advanced medical technologies aimed at improving patient outcomes.

Covalon Technologies Ltd. (CVALF) announced its fiscal 2022 Q4 and year-end results, reporting a 7% decline in revenue to $18.1M from $19.6M in the prior year. The company experienced a net loss of $9.7M, or $0.38 per share, compared to a profit of $23.5M in fiscal 2021. Operating expenses surged to $16.6M, driven by investments in marketing and leadership. Despite challenges, Covalon is optimistic about future revenue growth, especially in the U.S. market, where it secured its products in over 70 hospitals. The management commits to enhancing margins and profitability through operational improvements.